Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood DNA methylation and breast cancer risk: a prospective nested case-control study.

EBioMedicine·2026
Same author

A long-term image-derived AI-based risk model for primary prevention of breast cancer in individuals at high risk.

Science translational medicine·2026
Same author

Contribution of Risk Factors, Including Polygenic Score, to the Multifactorial Risk Assessment for the Implementation of Personalized Breast Cancer Screening: Insights from the PERSPECTIVE: Integration and Implementation Project.

Cancers·2026
Same author

Multi-cohort proteogenomic analyses reveal genetic effects across the proteome and diseasome.

Cell·2026
Same author

Endoxifen for mammographic density reduction-results from the KARISMA endoxifen trial.

Journal of the National Cancer Institute·2026
Same author

Statins and postmenopausal breast cancer risk; results from the KARMA cohort.

Cancer causes & control : CCC·2026
Same journal

Development and Validation of Salivary Exosomal Tri-RNA Liquid Biopsy in Esophageal Carcinoma: A Multicenter Study.

JCO precision oncology·2026
Same journal

Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment.

JCO precision oncology·2026
Same journal

Integrating DNA Mutations and RNA Expression of Cancer Driver Genes in Asian Rare Cancers: A Pan-Cancer Analysis.

JCO precision oncology·2026
Same journal

Sustained Response to Trametinib in Central Giant Cell Granuloma With <i>KRAS</i> Gain-of-Function Mutation: A Case Report.

JCO precision oncology·2026
Same journal

DNA Damage Response Alterations and Immune Checkpoint Blockade Outcomes Across Multiple Cancers.

JCO precision oncology·2026
Same journal

Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study.

JCO precision oncology·2026
See all related articles

Related Experiment Video

Updated: Jan 16, 2026

Quantification of Breast Cancer Cell Invasiveness Using a Three-dimensional 3D Model
08:08

Quantification of Breast Cancer Cell Invasiveness Using a Three-dimensional 3D Model

Published on: June 11, 2014

16.3K

Incorporating Continuous Mammographic Density Into the BOADICEA Breast Cancer Risk Prediction Model.

Lorenzo Ficorella1, Mikael Eriksson1,2, Kamila Czene2

  • 1Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.

JCO Precision Oncology
|September 26, 2025
PubMed
Summary
This summary is machine-generated.

This study improved breast cancer risk prediction by integrating automated mammographic density measurements into the BOADICEA algorithm. The enhanced model offers more accurate risk stratification for women, aiding in early detection and prevention strategies.

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.5K
Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
06:03

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Published on: February 6, 2020

7.0K

Related Experiment Videos

Last Updated: Jan 16, 2026

Quantification of Breast Cancer Cell Invasiveness Using a Three-dimensional 3D Model
08:08

Quantification of Breast Cancer Cell Invasiveness Using a Three-dimensional 3D Model

Published on: June 11, 2014

16.3K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.5K
Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
06:03

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Published on: February 6, 2020

7.0K

Area of Science:

  • Oncology
  • Radiology
  • Biostatistics

Background:

  • The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) is utilized for breast cancer (BC) risk prediction.
  • Current BC risk models often rely on manual mammographic density (MD) assessments (e.g., BIRADS), which are labor-intensive and may lead to data loss.
  • Automated tools offer a scalable solution for quantifying MD, but their integration into risk prediction models requires validation.

Purpose of the Study:

  • To enhance the BOADICEA algorithm (v7) by incorporating continuous, automated mammographic density (MD) measurements.
  • To evaluate the performance of the extended BOADICEA (v7.2) in predicting 5-year breast cancer risk using automated MD data.
  • To compare the predictive accuracy of the enhanced BOADICEA with models using traditional BIRADS classifications.

Main Methods:

  • Utilized data from the Karolinska Mammography Project for Risk Prediction of Breast Cancer cohort (n=60,276).
  • Estimated associations between continuous MD measurements (Volpara and STRATUS) and BC risk using Cox proportional hazards models in a training subset.
  • Incorporated hazard ratios (HRs) for MD into BOADICEA and assessed the extended model's predictive performance in a separate testing subset.

Main Results:

  • Continuous MD measurements, particularly from STRATUS and Volpara, were significantly associated with increased BC risk (HRs ranging from 1.27 to 1.48 per SD).
  • The extended BOADICEA (v7.2) demonstrated improved discrimination compared to BIRADS, with a 1%-4% increase in AUC.
  • The model reclassified approximately 11% of women to lower risk and 18% to higher risk categories based on 5-year BC risk using automated MD.

Conclusions:

  • Integrating continuous MD measurements, especially from automated tools, significantly improves breast cancer risk stratification.
  • The enhanced BOADICEA algorithm (v7.2) provides a more accurate and scalable approach to BC risk prediction.
  • Automated MD measures can be effectively utilized within advanced risk prediction models for clinical application.